HCM
Closed
Hutchmed Drc
15.41
+0.36 (+2.39%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 15.05
Day's Range: 15.26 - 15.53
Send
sign up or login to leave a comment!
When Written:
12.485
HUTCHMED, also known as Hutchison China MediTech, is a biopharmaceutical company that focuses on discovering, developing, and commercializing targeted therapies for the treatment of cancer and other diseases. The company has a presence in China, the United States, and Europe.
DRC, or Deciphera Resources Corporation, is a subsidiary of HUTCHMED that is focused on the development of kinase inhibitors for the treatment of cancer and other diseases. DRC's lead product candidate is a kinase inhibitor called ripretinib, which is being developed for the treatment of gastrointestinal stromal tumors (GIST) and other solid tumors.
HUTCHMED has a strong pipeline of drug candidates in various stages of development, including several kinase inhibitors and immune-oncology therapies. The company has partnerships and collaborations with major pharmaceutical companies, academic institutions, and research organizations to advance its drug development programs.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
DRC, or Deciphera Resources Corporation, is a subsidiary of HUTCHMED that is focused on the development of kinase inhibitors for the treatment of cancer and other diseases. DRC's lead product candidate is a kinase inhibitor called ripretinib, which is being developed for the treatment of gastrointestinal stromal tumors (GIST) and other solid tumors.
HUTCHMED has a strong pipeline of drug candidates in various stages of development, including several kinase inhibitors and immune-oncology therapies. The company has partnerships and collaborations with major pharmaceutical companies, academic institutions, and research organizations to advance its drug development programs.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








